Broughton Kathleen M, Sussman Mark A
San Diego State University Heart Institute and the Integrated Regenerative Research Institute.
Circ J. 2017 Jan 25;81(2):142-148. doi: 10.1253/circj.CJ-16-1228. Epub 2016 Dec 27.
Cardiovascular disease remains the leading cause of death worldwide and developing novel therapies to treat and cure the disease remains a high priority in the healthcare research community. Adult stem cells were successful in entering numerous clinical trials over the past 15 years in attempts to regenerate the heart. First-generation adult stem cell therapies for myocardial regeneration were highly promising in small animal models but realized benefits in humans were far more modest. Consequently, second-generation therapeutic approaches in early implementation phases have focused on enhancing cellular properties with higher survival and regenerative potential. Genetic programming dictates cellular fate, so understanding genetic composition and responses at the gene level to influence the outcome of the cell is essential for successful outcomes in regenerative medicine. Genetic editing is at the forefront of scientific innovation and as basic scientific research continues to expand upon understanding eukaryotic regenerative themes, a clearer vision of the possible future therapeutic approaches can be realized. Ultimately, enhancing biology and manipulating evolutional selection of cellular properties will be critical to achieving clinically relevant and biologically meaningful cardiac regeneration.
心血管疾病仍然是全球主要的死亡原因,开发治疗和治愈该疾病的新疗法仍然是医疗保健研究界的高度优先事项。在过去15年中,成体干细胞成功进入了众多临床试验,试图使心脏再生。第一代用于心肌再生的成体干细胞疗法在小动物模型中前景广阔,但在人类身上实现的益处却要小得多。因此,处于早期实施阶段的第二代治疗方法专注于增强细胞特性,使其具有更高的存活率和再生潜力。基因编程决定细胞命运,因此了解基因组成以及基因水平的反应以影响细胞结果对于再生医学的成功至关重要。基因编辑处于科学创新的前沿,随着基础科学研究在理解真核生物再生主题方面不断扩展,可以更清晰地展望未来可能的治疗方法。最终,增强生物学特性并操纵细胞特性的进化选择对于实现临床相关且具有生物学意义的心脏再生至关重要。